Effects of atorvastatin on asthmatic patients
Phase 1
- Conditions
- Asthma.Asthma
- Registration Number
- IRCT138903114085N1
- Lead Sponsor
- Research assistant of Guilan University of Medical Science
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- All
- Target Recruitment
- 50
Inclusion Criteria
aged 18 to 70 years, moderate to severe persistent asthma, under maintenance therapy with high dose inhaled corticosteroid and any dose of oral corticosteroid, under stable medication for the four preceding weeks before randomization, being admitted to respiratory clinic of Razi medical center (Rasht, Guilan province)
Exclusion criteria: current smoking or ex-smoking more than 5 pack–year, pregnancy, lactation, any associated diseases, receiving statins or any statin interacting drugs, occurrence of any asthmatic attack during the study
Exclusion Criteria
Not provided
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method FEV1. Timepoint: at the begining of the study and every 1 month interval until 2 months. Method of measurement: spirometry.;FVC. Timepoint: at the begining of the study and every 1 month interval until 2 months. Method of measurement: spirometry.;FEV1/FVC. Timepoint: at the begining of the study and every 1 month interval until 2 months. Method of measurement: spirometry.;FEF25-75%. Timepoint: at the begining of the study and every 1 month interval until 2 months. Method of measurement: spirometry.;Hs-CRP. Timepoint: at the begining of the study and every 1 month interval until 2 months. Method of measurement: blood sample,micg/ml.;ESR. Timepoint: at the begining of the study and every 1 month interval until 2 months. Method of measurement: blood sample, mm/h.;Asthma control level. Timepoint: at the begining of the study and every 1 month interval until 2 months. Method of measurement: asthma control test (ACT).
- Secondary Outcome Measures
Name Time Method Creatinine kinase(CPK). Timepoint: at the begining of the study and every 1 month interval until 2 months. Method of measurement: blood sample, IU/L.;Liver function test. Timepoint: at the begining of the study and every 1-month interval until 2months. Method of measurement: blood sample,IU/L.;(Beta hCG) pregnancy test. Timepoint: at the begining of the study and every 1 month interval until 2 months. Method of measurement: blood sample, mIU/ml.